Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Two House subcommittees are holding hearings on the baby formula crisis. One will focus on the Food and Drug Administration and the formula makers. The other will look at the effects of the shortage.
-
The Biden administration says help is on the way to address the nationwide baby formula shortage. How would the Defense Production Act, a legal vestige of the Cold War era, help?
-
NPR has obtained the government's $5.3 billion contract for the first 10 million courses of Paxlovid, an antiviral pill for COVID-19. Here's what's in it. -
The Biden administration wants to buy and send a billion free at-home COVID tests to Americans. Here's what we know so far about the contracts in terms of price, timeline and more.
-
Former scientific head of Operation Warp Speed Moncef Slaoui explains why he is confident in existing vaccines' protection against omicron and how soon a variant-specific booster could be developed.
-
How much money have Pfizer and Moderna made off their COVID-19 vaccines? They're shaping up to be the most lucrative pharmaceutical products ever.
-
Pfizer says it is willing to share rights to its COVID-19 pill, Paxlovid. It's an oral antiviral drug that can be taken outside the hospital, which could be a help to low income countries.
-
Kids who need a hormone-blocking drug to prevent premature puberty have lost an off-label option. The company that makes the medicine, which is 1/8 the cost of the FDA-approved version, withdrew it.
-
Immediately after the Food and Drug Administration authorized Pfizer's vaccine, the company delivered fewer doses than its government contract projected. Federal officials say they didn't know why.
-
President Biden threw his support behind a World Trade Organization proposal that would waive intellectual property protections for COVID-19 vaccines — allowing countries to make their own vaccines.
